What we do Krsnaa Diagnostics offers radiology, pathology, and teleradiology services through an extensive network of 3600+ centers across 18 Indian states, focusing on affordable diagnostics. |
Founded in 2,010 |
Market share Among India’s fastest-growing diagnostics providers, with a strong presence in PPP and non-metro markets covering 18 states and 3600+ centers. |
Problem solved Expands access to affordable, quality diagnostic services including radiology and pathology in tier II/III cities and remote areas. |
Top clients or who we serve B2C and B2B segments including individual patients, hospitals, and government partnerships in diagnostic healthcare. |
Key management Rajendra Mutha (Chairman), Yash Mutha (Managing Director), Mitesh Dave (Group CEO), Pallavi Bhatevara (Whole-time Director). |
Our journey and innovations Started in 2010, expanded via PPP since 2012, IPO in 2021, grew from 660 centers in FY18 to 5200+ in FY25, pioneered affordable diagnostics model. |
Where we operate Operates across India in 18 states and union territories, focusing on underserved non-metro and tier II/III towns. |
Top products or what we offer Integrated diagnostic services including X-ray, CT Scan, MRI, Mammography, blood and urine tests, tele-reporting, and pathology labs. |
Top brands Leading diagnostic brand known for NABH-accredited tele-radiology hub, extensive center network, and cost-effective service offerings. |
Raw materials needed Diagnostic equipment and medical testing consumables including reagents and imaging devices. |
Raw materials supplier Suppliers include medical equipment manufacturers and reagent providers specific names not disclosed. |
Recurring vs cyclical contribution Revenue predominantly recurring from diagnostic tests with steady growth driven by expansion and PPP contracts. |
Our industry position One of the largest integrated diagnostics providers in India with strong margins and rapid network expansion. |
Financial highlights FY25 consolidated revenue Rs. 717 crores, PAT Rs. 77.6 crores, EBITDA margin around 27%, CAGR revenue ~34%, PAT ~49%. |
Geographical revenue split Diversified across West, South, North, East India with West and North regions contributing major revenue shares. |
Order book Strong pipeline of projects including Rajasthan pathology expansion and ongoing PPP contracts. |
Whats driving growth PPP partnerships, expansion into tier II/III cities, retail network growth, affordable pricing, NABH accreditations. |
Our future plans Scaling CT/MRI centers, expanding retail presence in new states, enhancing pathology network, and increasing strategic healthcare partnerships. |
Our green promise Focus on energy efficiency, paperless operations, and monitoring energy usage to minimize environmental impact. |
Our people and values Employs 350+ radiologists, 120+ pathologists, 3000+ professionals emphasizing quality, inclusion, and patient care. |
Key challenges ahead Managing rapid expansion, maintaining service quality, competition, regulatory compliance, and operational scalability. |
Interesting facts India’s first PPP diagnostic player to IPO, offers diagnostics at 50-70% below market rates, serves 81+ million patients since inception. |
Risks and strategy Risks include operational scale challenges; mitigated by strong governance, quality focus, and diversified service offerings. |
